 
            IndraLab
Statements
                                      reach
                                
                                  
                                
                                
          
          
                                  "These data demonstrate that CD8 + T cells, but not CD4 + T cells, are the primary effector cells underlying the combination treatment in these tumor models.Finally, to ascertain whether USP2 inhibition potentiates the efficacy of PD-1/PD-L1 blockade by enhancing p53 function in a tumor cell autonomous manner, we also examined the effects of combination therapy in Balb/c mice bearing p53-null EMT6 tumors."